StepStone backs separate multi-asset deal on back of Gyrus’s single asset

The firm was a participating investor in a single-asset CV for Essential Pharma.

SECONDARIES INVESTOR

Register to unlock this content

• Daily global secondaries market news and intelligence
• Curated insights to keep you ahead of GP-led and LP-led secondaries
• Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
• Access to proprietary research and reports
• Selected fund performance and investor activity data

Register nowFind out more

DealsNorth AmericaWestern EuropeSecondariesGP-Leds